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Environmental and genetic factors are thought to
interact in the manifestation of psoriasis, but know-
ledge about the involved genes and antigens is
incomplete. This study has focused on the association
between psoriasis and inherited variations in xeno-
biotic metabolism and cytokine production as two
components that may influence cutaneous immune
responses to foreign substances. Polymorphisms of
N-acetyltransferase 2, glutathione S-transferases T1
and M1, and promoter polymorphisms of the genes
encoding for tumor necrosis factor-a and interleukin-
10 were investigated in 151 Caucasian patients with
psoriasis (100 with type I and 51 with type II psoriasis)
and in 123 healthy controls. Polymorphisms were
detected by polymerase chain reaction-based methods,
restriction enzyme analysis, and direct sequencing.
There were no significant differences in the distribution
of enzyme polymorphisms or point mutations at posi-
tion –1082 of the interleukin-10 promoter between the
psoriasis groups and the control group. The G→A
Psoriasis is a chronic inflammatory skin disorder affectingabout 2% of Caucasian populations (Lomholt, 1963).Population and twin studies provide clear evidence ofa heritable component to the etiology (Elder et al,1994), and a strong association has been established
between the disease and genes of the major histocompatibility
complex on human chromosome 6. The highest relative risk (nine
to 15 times normal) has been found for HLA-Cw6 (Tiilikainen
et al, 1980), and the HLA association of psoriasis was shown to
include the B and C loci (HLA-B17, HLA-B37, HLA-B57) and
extend to the class II genes DRB1*0701, HLA-DQA1*0201, and
HLA-DQB1*0303 (Schmitt-Egenolf et al, 1993). A classification
of disease subtypes has been proposed on the basis of differences in
the age of onset and frequency of HLA (Henseler and Christophers,
1985). According to this classification Caucasian patients with type
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polymorphism at position –238 of the tumor necrosis
factor-a promoter (TNFa-238*A allele) was more
common in type I psoriasis (27%) than in the controls
[9.8%; odds ratio 3.4 (95% confidence interval 1.6–
7.2); p J 0.0012; pcorr J 0.018]. Surprisingly, this
overrepresentation of the tumor necrosis factora – 238*A
allele was observed in male patients [4.1 (1.5–11.0);
p J 0.0046; pcorr J 0.064] but not in female patients
[1.8 (0.5–6.5); p J 0.5]. The G→A polymorphism at
position –308 of the tumor necrosis factor-a promoter
was less frequent in type I psoriasis (23%) compared
with controls (35.7%), although the negative associ-
ation was weak [0.54 (0.3–0.97); p J 0.041; pcorr J not
significant]. The distribution of the TNFa-238*A and
TNFa-238*A alleles was similar in type II patients and
controls. Our results suggest that male carriers of the
G→A polymorphism at position –238 of the tumor
necrosis factor-a promoter are at an increased risk
to develop early-onset psoriasis. Key words: cytokines/
heritable factors/immune reaction/xenobiotic metabolism. J
Invest Dermatol 113:214–220, 1999
I psoriasis (onset before the age of 40 y) are characterized by a
high proportion of carriers of Cw6, B57, and DR7, whereas in
type II psoriasis (onset beyond 40 y), HLA-Cw2 is increased and
the association with Cw6 is weaker (Henseler, 1997). The concept
of disease subtypes that differ in their genetic background was
supported by the demonstration of a strong association between
the extended risk haplotype Cw6-B57-DRB1*0701-DQA1*0201-
DQB1*0303 and German patients with familial early-onset but
not sporadic late-onset psoriasis (Schmitt-Egenolf et al, 1996).
Whereas these data suggest that at least one predisposing gene
resides in the HLA region, a more complex genetic basis is indicated
by genome scans in affected families that have yielded additional
susceptibility loci on chromosomes 17q (Tomfohrde et al, 1994)
and 4q (Matthews et al, 1996).
Recent studies into the genetic factors associated with allergic
asthma, rheumatoid arthritis, and lupus erythematosus took advant-
age of the increasing knowledge about disease-specific immunologic
abnormalities and the genetic control of immunoregulatory
mechanisms such as the production of protective or harmful
cytokines (Eskdale et al, 1998a; Lim et al, 1998; Mok et al, 1998).
Such an approach may also be considered when investigating the
genetics of psoriasis, the psoriatic inflammatory process being
characterized by a disturbance of the local cytokine network
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with overexpression of proinflammatory mediators, such as tumor
necrosis factor (TNF)-α (Uyemura et al, 1993; Schlaak et al, 1994),
and a relative deficiency of anti-inflammatory factors such as
interleukin (IL)-10 (Nickoloff et al, 1994; Asadullah et al, 1998).
Importantly, several findings suggest that both cytokines play a
critical part in the disease pathogenesis. TNF-α together with
other mediators induces the production of IL-8 in fibroblasts and
keratinocytes (Larsen et al, 1989; Barker et al, 1990) that acts as a
chemotactic factor for T cells and neutrophils and is strongly
upregulated in psoriatic epidermis (Kulke et al, 1996). Immune cell
traffic into psoriatic lesions may also be enhanced by TNF-α via
induction of adhesion molecules on endothelial cells (Uyemura
et al, 1993). Finally, TNF-α and IFN-γ stimulate the production
of transforming growth factor-α by epidermal cells that may together
with IL-8 be involved in autocrine stimulation of keratinocyte
proliferation (Barker et al, 1991). On the other hand, IL-10 is a
potent antagonist of cutaneous T cell-mediated immune responses
(Ferguson et al, 1994), suppresses epidermal cell growth in vitro
(Michel et al, 1997), and has strong anti-psoriatic effects when
administered to affected patients (Asadullah et al, 1998; Reich
et al, 1998).
Polymorphisms have now been detected in the promoter regions
of the TNFα and IL10 gene that affect cytokine production. The
G→A polymorphism at position –308 of the TNFα promoter
(TNFα-308*A allele) is associated with a 6–7-fold increased tran-
scriptional activity (Wilson et al, 1997). Monocytes of carriers of
another G→A polymorphism at position –238 (TNFα-238*A
allele) show a higher TNF-α production after stimulation than
monocytes isolated from homozygous carriers of the TNFα-238*G
allele, although in the original study this finding was not statistically
significant (Pociot et al, 1995). In contrast, the IL10–1082*A allele
(G→A transition at position –1082 of the IL10 promoter) is
associated with decreased inducible levels of IL-10 in peripheral
blood mononuclear cells (Turner et al, 1997).
Given the observed constellation of cytokine expression in
psoriatic skin it is natural to ask whether these promoter polymorph-
isms are associated with the disease. In the case of TNFα promoter
polymorphisms, research has also been stimulated by the fact that
the gene for TNF-α is located within the class III region of the
major histocompatibility complex between HLA-B and HLA-DR
(Campbell and Trowsdale, 1993), and two recent studies have
presented evidence for an association between the TNFα-238*A
allele and early-onset psoriasis (Arias et al, 1997; Ho¨hler et al, 1997).
In this study a case-control design was used to reinvestigate the
distribution of the TNFα-238*A and TNFα-308*A alleles in a
larger series of patients with early- and late-onset psoriasis compared
with healthy individuals, and to search for associations between the
disease and IL-10 promoter polymorphism. We extended our study
to functionally relevant polymorphisms of N-acetyltransferase 2
(NAT2), glutathione S-transferases (GST) M1 and T1, because
these have lately been recognized as heritable risk factors for the
development of cutaneous inflammatory reactions in response to
exogenous stimuli such as ultraviolet irradiation (Kerb et al, 1997)
and contact allergens (Schnuch et al, 1998).
MATERIALS AND METHODS
Patients We included only German Caucasians in this study. One-
hundred patients with early-onset psoriasis (onset not later than at the age
of 40 y and a positive family history) and 51 patients with type II psoriasis
(onset after the age of 40 y, negative family history) were recruited at the
Department of Dermatology, University Clinic of Go¨ttingen. All patients
had psoriasis vulgaris and none suffered from other pathologic skin
conditions. The median age of the type I group was 41 y (range 11–92)
and included 33 female (33%) and 67 male subjects (67%). The median
age at onset was 25 y (range 3–39). The type II group had a median age
of 61 y (range 42–86), including 22 female (43.1%) and 29 male patients
(56.9%). The median age at onset was 55 y (range 41–85). The control
population consisted of 123 locally recruited, unrelated, healthy volunteers
(56 females, 67 males). Health status was determined by skin examination
and a record of the personal and familial medical history. Individuals with
a history suspicious of atopy or contact allergy were excluded from the
control group.
Determination of the NAT2 phenotype Systemic N-acetyltransferase
activity was determined using the urinary caffeine metabolite ratio of
5-acetylamino-6-formylamino-3-methyluracil to 1-methylxanthine as out-
lined by Grant et al (1984). Participants were asked to ingest a beverage
containing caffeine. Urine was collected at least 4 h later, acidified, and
stored at –80°C. Analysis of caffeine metabolites was done within 3 weeks,
because the quotient of 5-acetylamino-6-formylamino-3-methyluracil/
1-methylxanthine is stable for this period under the given storing conditions.
Extraction and separation of caffeine metabolites were performed according
to Grant et al (1984) with the exception that formic acid instead of
acetic acid was used to improve the stability of the compounds during
chromatography. Thus, 0.025% formic acid with methanol (99% vol/
vol) served as mobile phase on a Kontron high-performance liquid
chromatography (Kontron M 800 with diode array detector; Neufahrn,
Germany) and a Knauer 100 C18 column (Knauer, Berlin, Germany).
Genotyping for NAT2, GST T1, and M1 Blood was collected in
ethylenediamine tetraacetic acid tubes. Extraction of DNA from buffy
coats was performed by a salting out procedure. Briefly, lymphocytes were
collected at 400 g and 4°C, and lysed in 50 mM trisect pH 8.0, 20 mM
ethylenediamine tetraacetic acid pH 8.0 and 2% sodium dodecyl sulfate.
Protein was digested with Proteinase K (6 h at 56°C) and pelleted with
6 M NaCl following centrifugation at 5000 3 g for 20 min. DNA was
precipitated with 1.5 3 Vol. 100% ethanol (pa). DNA yields were between
0.1 and 1 µg per µl.
The genotype of NAT2 was characterized by polymerase chain reaction
and restriction enzyme analysis (PCR–RFLP) at nucleotide positions 191,
282, 341, 481, 590, 803, and 857 as described by Cascorbi et al (1995)
with the published modifications (Cascorbi et al, 1996). From the mutation
pattern, seven different alleles were determined, including the wild-type
allele NAT2*4 and the six mutant alleles NAT2*5a, NAT2*5b, NAT2*5c,
NAT2*6a, NAT2*7b, and NAT2*12a.
Homozygous deletions of GSTM1 and GSTT1 were characterized
simultaneously with a multiplex PCR with β-globin as internal standard.
Primers for GST M1 were according to Bell et al (1992). Primers for GST
T1 were according to Pemble et al (1994). Each PCR contained µ200 ng
of genomic DNA, 11.25 pmol dNTPs (Amresco, Solon, OH), 20 pmol
of each primer (Eurogentec, Seraing, Belgium), 1 U Taq polymerase
(Appligene Oncor, Heidelberg, Germany), and Taq-buffer according to
the supplier in a final volume of 30 µl. The samples were denaturated for
4 min at 94°C, and subsequently amplified with 31 cycles of 94°C, 66°C,
and 72°C for 1 min each, without a final extension time. PCR products
were separated on a 2% agarose gel (molecular biology grade; Eurogentec).
Enzyme expression in skin biopsies, dendritic cells, and keratino-
cytes To study the expression of polymorphic enzymes in the skin, 3 mm
punch biopsies were taken from active plaque lesions from three psoriatic
patients participating in the study that had not received any topical treatment
for at least 2 wk and any systemic treatment including phototherapy for
at least 4 wk. Skin specimens were also collected from three healthy
volunteers. Written informed consent was obtained in all cases. Biopsies
were immediately snap frozen in liquid nitrogen and stored at –70°C.
Total mRNA was extracted from 30 consecutive 20 µm sections using
Trizol (Gibco, Eggenstein, Germany) according to the instructions supplied
by the manufacturer. RNA was also obtained from peripheral blood
mononuclear cells of the same donors. The absence of gDNA contamination
was confirmed by running a β-actin PCR. Reverse transcription was then
performed with Superscript II (Gibco) according to the manufacturer’s
protocol.
Expression of polymorphic enzymes was also analyzed in peripheral
blood derived dendritic cells and freshly isolated Langerhans cells. The
former were generated according to a modified published protocol (Pickl
et al, 1996). Briefly, CD141 cells were positively selected from peripheral
blood mononuclear cells of healthy volunteers (n 5 3) by high gradient
magnetic sorting using the VARIOMACS technique (Miltenyi Biotec,
Bergisch Gladbach, Germany). Isolated CD141 cells (purity . 85%) were
cultured for 5 d in RPMI 1640/5% fetal bovine serum, containing 50 ng
recombinant human (rh) IL-4 (Pharma Biotechnologie, Hanover, Germany)
per ml and 50 ng rhGM-CSF (kindly provided by the Schering-Plough
Research Institute, Kenilworth, NJ) per ml. After this time, part of the
cells were subjected directly to mRNA extraction (referred to as immature
dendritic cells). The remaining cells were incubated for 3 additional days
with 100 ng TNF-α (Pharma Biotechnologie) per ml and 50% vol/vol
monocyte conditioned medium (Romani et al, 1996). Sixty to 90% of the
216 REICH ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Figure 1. Expression of NAT2 and GST in
PBMC, skin, dendritic cells, and keratinocytes.
(a) Left: example for the constitutive expression of
NAT2 in healthy skin, lesional psoriatic skin, and
peripheral blood mononuclear cells (PBMC) from the
same donors as determined by reverse transcription–
PCR. Expression of NAT2 was also detected in
immature (DCd5) and mature (DCd8) peripheral
monocyte-derived dendritic cells (see Materials and
Methods). Right: constitutive expression of NAT2
in cultured keratinocytes (KC) and freshly isolated
epidermal Langerhans cells (LC). PCR of gDNA
samples prepared from lymphocytes of the corres-
ponding individuals served as positive control. (b)
Multiplex PCR with β-globin as internal standard
demonstrating constitutive expression of GST M1
but not GST T1 in PBMC, healthy and lesional
psoriatic skin, and immature (DCd5) and mature
dendritic cells (DCd8). For each individual the muta-
tion pattern (M1–, homozygous deletion of GST M1;
T1–, homozygous deletion of GST T1) as determined
by gDNA analysis is shown compared with control
gDNA samples with confirmed combined homozy-
gous deletion of both enzymes (M1–T1–) or absence
of gene deletions (M11T11). X, negative control
reaction without genomic or cDNA.
resulting cell population displayed a dendritic morphology in cytospin
preparations (‘‘veils’’), and expressed the phenotype of mature dendritic
cells as measured by fluorescence-activated cell sorter analysis (CD831,
CD861, HLA-DRhigh, CD401, CD1a1, CD14–). The cells produced IL-
12p40, IL-1β, and TNF-α but only minor quantities of IL-10 and were
potent stimulators of proliferatory responses in resting T cells (referred to
as mature dendritic cells; data not shown).
Langerhans cells (.95% CD1a1 by fluorescence-activated cell sorter
analysis) were isolated from the foreskin of individuals undergoing circum-
cision as described (Simon et al, 1995). Keratinocytes were prepared from
individuals undergoing plastic surgery according to Boyce and Ham (1983).
Reverse transcription–PCR was performed with keratinocytes derived
from the second passage of culture (.95% cytokeratin positive, ,1%
CD1a positive). Extraction of total mRNA from suspensions of these cells
and cDNA synthesis were performed as above.
Primers for the detection of NAT2 cDNA were 59-GAC-ATT-GAA-
GCA-TAT-TTT-GAA-AG-39 (sense; Woolhouse et al, 1997) and 59-
ACC-CAG-CAT-CGA-CAA-TGT-AAT-TCC-TGC-CCT-CA-39 (anti-
sense; Cascorbi et al, 1996), which amplify a 369 bp fragment. PCR
conditions were as follows: denaturation at 94°C for 4 min, followed by
30 cycles of 94°C for 30 s, 60°C for 1 min, and 74°C for 4 min, and a
final extension time of 10 min.
Primers and PCR conditions for GST T1 and M1 were the same as for
the gDNA analysis. The sequence amplified from GST M1 gDNA
comprises 219 bp including a 86 bp intron (Zhong et al, 1993). Therefore,
amplification of cDNA should yield a 133 bp fragment (Fig 1b).
Analysis of TNFa promoter polymorphisms Polymorphisms of the
TNFα promoter at position –238 were analyzed by PCR–RFLP according
to Day et al (1998). Allelic variations at position –308 were detected by
allele-specific PCR as described by Couchane et al (1997).
Analysis of the polymorphism at position –1082 of the IL10
promoter Base pair substitutions at position –1082 of the IL10 gene
(Turner et al, 1997) were detected by cycle sequencing of PCR products
generated with the following primers: IL-10 sense: 59-ATCCAAGAC-
AACACTACTAA-39 (Turner et al, 1997), and anti-sense: 59-GTGGAA-
GAAGTTGAAATAAC-39 (Mok et al, 1998). PCR conditions were 35
cycles of 94°C, 51°C, and 72°C for 1 min each with a final extension
time of 10 min at 72°C. The anti-sense primer was used for cycle
sequencing on an ABI Prism 310 Genetic Analyzer (Perkin Elmer ABI,
Foster City, CA) equipped with the Data Collection 1.02 and Sequencing
Analysis 3.0 software. PCR fragments were purified by ultrafiltration via
Microcon 100 filters (Millipore, Bedford, MA). The purified fragments
were amplified and labeled with Big-Dye-Terminator-Ready-Reaction-
Mix (Perkin Elmer ABI) as follows: 4 µl of mix, 110 ng DNA and 3.2 pmol
primer in a final reaction volume of 20 µl. Following 25 cycles of 95°C
for 30 s, 50°C for 15 s, and 60°C for 4 min, labeled DNA was separated
by Na-acetate/ethanol-precipitation.
Statistical analysis The frequencies of cytokine promoter and enzyme
alleles were compared between patients with type I psoriasis, type II
psoriasis, and controls by the two-sided Fisher’s exact test (Kleinbaum et al,
1982). The Bonferroni method was used to adjust for multiple comparison.
The frequencies of seven variables NAT2*4, GSTT1*0, GSTM1*0,
GSTT1*0/M1*0, TNFα-238*A, TNFα-308*A, and IL10–1082*A were
compared separately between the early-onset and the control groups and
the late-onset and the control groups, and the initial p-values were
multiplied by 14 (Rothmann and Greenland, 1998). Odds ratios and 95%
confidence intervals were calculated for each variable. In each group the
distribution of TNF-α and IL-10 promoter genotypes was tested for
deviations from Hardy–Weinberg equilibrium by an exact test (Guo and
Thompson, 1992). Linkage disequilibrium between the polymorphisms at
positions –238 and –308 of the TNFα promoter was also tested by an
exact test (Zaykin et al, 1995). The prism 2.01 software (GraphPad, San
Diego, CA) was employed for calculation of the Fisher’s exact test and the
95% confidence interval.
RESULTS
NAT2, GST M1, and T1 are expressed in normal and
psoriatic skin, keratinocytes and dendritic cells By reverse
transcription–PCR we detected NAT2 expression in freshly isolated
peripheral blood mononuclear cells and skin biopsies from healthy
donors and psoriasis patients (Fig 1a). As epidermal dendritic cells
and keratinocytes represent the first line of cells that may handle
transepidermally absorbed antigens, we also investigated the expres-
sion of NAT2 in freshly isolated Langerhans cells and keratinocytes,
and expression of NAT2 mRNA was confirmed in both cell types
(Fig 1a). Furthermore, NAT2 expression was detected in immature
dendritic cells cultured from peripheral blood in the presence
of granulocyte-macrophage colony-stimulating factor and IL-4.
Expression of NAT2 was maintained after induction of maturation
by incubation with TNF-α (Fig 1a).
Of the polymorphic GST investigated, only GST M1 was
reproducibly detected in peripheral blood mononuclear cells, nor-
mal and psoriatic skin, and immature and mature dendritic cells,
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Table I. Frequencies of enzyme polymorphisms in the
investigated groups
Psoriasis group
Control group Early onset, Late onset,
Enzyme n/total (%) n/total (%) n/total (%)
NAT2rapida 37/123 (30.1%) 40/100 (40%) 19/51 (37.3%)
GST T1-b 18/123 (14.6%) 8/100 (8%) 10/51 (19.6%)
GST M1-b 62/123 (50.4%) 57/100 (57%) 28/51 (54.9%)
GST M1-T1-c 7/123 (5.7%) 2/100 (2%) 7/51 (13.7%)d
aNAT2 wild-type allele homozygous or heterozygous.
bHomozygous deletion of GST T1 or M1, respectively.
cCombined homozygous deletion of GST T1 and M1.
dp50.0073, pcorr50.1; late onset compared with early onset psoriasis.
Table II. Frequencies of rapid acetylator allelic
combinations
Psoriasis group
Control group Early onset Late onset
(37/123)a (40/100) (19/51)
Genotype n (%) n (%) n (%)
NAT2*4/2*4 5 (4.1) 5 (5) 2 (3.9)
NAT2*4/2*5b 13 (10.6) 15 (15) 9 (17.6)
NAT2*4/2*6a 18 (14.6) 16 (16) 8 (15.7)
NAT2*4/2*5c 0 3 (3) 0
NAT2*4/2*7b 0 1 (1) 0
NAT2*4/2*12a 1 (0.8) 0 0
aGenotypically rapid acetylators/total.
whereas the cutaneous expression of GST T1 was weak or
absent (Fig 1b).
Lack of association between psoriasis and polymorphisms
of xenobiotic metabolizing enzymes at the genotypic
level There were no significant differences in the distribution of
genotypically rapid acetylators (presence of at least one NAT2*4
wild-type allele) or rapid acetylator allelic combinations between
the psoriasis groups and the control group (Tables I and II).
Material for a phenotypic analysis (see Materials and Methods) was
available from the first 91 patients with psoriasis (55 type I; 36 type
II) and 84 controls consecutively enrolled into the study. The
proportions of genotypically rapid acetylators in psoriasis patients
and controls in this subgroup were similar to those observed in the
entire study population (controls: 29.8%, type I: 43.6%, type II:
37.8%), and differences were not significant. When the NAT2
phenotype was determined, however, a rapid acetylator phenotype
was significantly more common among patients with early-onset
psoriasis (45.5%) than among healthy controls [23.8%; 2.7 (1.3–
5.5); p 5 0.0096; Fig 2].
Frequencies of homozygous gene deletions of GST T1
(GSTT1*0) or GST M1 (GSTM1*0) that lead to abolition of
enzymatic function were similar among psoriasis patients and
controls (Table I). Combined homozygous deletions of both
enzymes were more common in type II (13.7%) than in type I
patients (2%), but the difference was not significant after correction
for multiple comparisons [7.8 (1.6–39.1); p 5 0.0073; pcorr 5 0.1].
There was no association of the GSTM1*0/GSTT1*0 genotype
with late-onset psoriasis compared with controls [2.6 (0.9–8); p 5
0.12]. Frequencies of NAT2, GST T1 and M1 polymorphisms
were similar among male and female patients.
The TNFa-238*A allele is increased in male but not in female
patients with early-onset psoriasis The allele frequencies of
the TNFα-238 and TNFα-308 polymorphism in the control group
were similar to those reported in other studies for west European
Caucasians (D’Alfonso and Richiardi, 1994; Pociot et al, 1995;
Figure 2. Association of a rapid acetylator phenotype with early-
onset psoriasis. Systemic NAT2 activity expressed as the ratio of caffeine
metabolites 5-acetylamino-6-formylamino-3-methyluracil and 1-methyl-
xanthine in (a) 84 noncontact allergic, nonatopic healthy controls and (b)
55 patients with early-onset psoriasis. The values were logarithmically
transformed; a log ratio , 0 corresponds to a slow, a log ratio . 0 to a
rapid acetylator phenotype. The difference between study and control
group was significant (two-sided Fisher’s exact test: p 5 0.0096).
Arias et al, 1997). We found a significantly increased frequency of
the TNFα-238*A allele in patients with early-onset psoriasis (27%)
compared with controls [3.4 (1.6–7.2); p 5 0.0012; pcorr 5 0.017],
whereas the frequency in late-onset psoriasis (19.6%) compared
with controls was not increased [1.7 (0.7–4.5); p 5 0.3] (Table III).
Homozygosity for the TNFα-238*A allele was present in one
patient of the type I group, and none of the type II patients or
controls, which is probably due to chance as homozygosity accord-
ing to the Hardy–Weinberg law can be expected in 2, 0.3, and 0.3
individuals of the type I, type II, and control groups, respectively.
When the distribution of the TNFα-238*A allele was investigated
separately in male and female patients, an increased frequency was
only detected in male but not in female patients with early-onset
psoriasis (Table IV).
The frequency of the TNFα-308*A allele in type I patients
(23%) was lower than in the control group (35.8%); however, this
finding was only of borderline significance [0.5 (0.3–0.97); p 5
0.041; pcorr 5 0.6]. As the negative association between early-
onset patients and TNFα-308*A could result from a linkage
disequilibrium between TNFα-238*A and TNFα-308*G alleles,
it is noteworthy that in accordance with the literature (Ho¨hler
et al, 1997) variations at the –238 locus were independent from
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those at the –308 locus. Independence was also suggested by the
observation that the TNFα-308*A allele was similarly distributed
among male and female type I patients. The association between
male patients with type I psoriasis and the TNFα-238*A/-308*G
haplotype [4.8 (1.5–15.1); p 5 0.0047; pcorr 5 0.066] was not
stronger than the association found for TNFα-238*A alone.
The IL10–1082*A allele was in Hardy–Weinberg equilibrium
and no significant associations were found with early- or late-onset
psoriasis (Table III). Frequencies of the IL10–1082*A allele were
comparable in males and females in all groups.
Interactions between enzyme and promoter polymorphisms
To address the issue of possible interactions between cytokine
promoter and enzyme polymorphisms we assessed the frequencies of
Table III. Frequencies of cytokine promoter
polymorphisms in the investigated groups
Psoriasis group
Control group Early onset, Late onset,
n/total (%) n/total (%) n/total (%)
TNFα-238
G/G 111/123 (90.2%) 73/100 (73%) 43/51 (84.3%)
G/A 12/123 (9.8%) 26/100 (26%)a 8/51 (19.6%)
A/A 0 1/100 (1%) 0
TNFα-308
G/G 79/123 (64.2%) 77/100 (77%) 36/51 (70.6%)
G/A 42/123 (34.1%) 23/100 (23%)b 15/51 (29.4%)
A/A 2/123 (1.6%) 0 0
IL10-1082
G/G 27/123 (22%) 26/100 (26%) 12/51 (23.5%)
G/A 67/123 (54.5%) 48/100 (48%) 22/51 (43.1%)
A/A 29/123 (23.6%) 26/100 (26%) 17/51 (33.3%)
ap50.0012, pcorr50.017; G/A and A/A versus G/G in early onset psoriasis
compared with controls.
bp50.041, pcorr50.6; G/A and A/A versus G/G in early onset psoriasis compared
with controls.
Table IV. Gender-specific distribution of TNFa-238
genotypes
Psoriasis group
Control group Early onset Late onset
female male female male female male
(n567) (n556) (n533) (n567) (n522) (n529)
TNFα-238 n (%) n (%) n (%) n (%) n (%) n (%)
G/G 46 (91) 50 (89) 28 (85) 45 (67) 18 (82) 25 (86)
G/A 6 (9) 6 (11) 5 (15)a 21 (31)b 4 (18) 4 (14)
A/A 0 0 0 1 (2) 0 0
aOR51.8 [95% CI 0.5–6.5]; p50.5; G/A and A/A versus G/G in females with
type I psoriasis compared with female controls.
bOR54.1 [95% CI 1.5–11]; p50.0046, pcorr50.064; G/A and A/A versus G/G
in males with type I psoriasis compared with male controls.
Table V. Frequencies of combined polymorphisms in males
Control Early onset
(males556) (males567)
Genotype n/males (%) n/males (%) OR (95% CI) p
NAT2*4 16/56 (28.6) 26/67 (38.8) 1.6 (0.7–3.4) p5NS
GSTM1*0 29/56 (51.8) 39/67 (58.2) 1.3 (0.6–2.7) p5NS
IL10-1082*A 45/56 (80.4) 49/67 (73.1) 0.7 (0.3–1.6) p5NS
TNFα-238*A 6/56 (10.7) 22/67 (32.8) 4.1 (1.5–11.0) p50.0046; pcorr50.064
TNFα-238*A/NAT2*4 1/56 (1.8) 9/67 (13.4) 8.5 (1.1–69.6) p50.021; pcorr5NS
TNFα-238*A/GSTM1*0 4/56 (7.1) 12/67 (17.9) 2.8 (0.9–9.4) p5NS
TNFα-238*A/IL10-1082*A 5/56 (8.9) 17/67 (25.4) 3.5 (1.2–10.1) p50.02; pcorr5NS
combined polymorphisms in the psoriasis groups and controls. The
NAT2*4/GSTM1*0, NAT2*4/IL10–1082*A, and GSTM1*0/
IL10–1082*A combined polymorphisms were similarly distributed
among type I patients, type II patients, and controls.
There was evidence for interactions between the TNFα-238
polymorphism and enzyme polymorphisms. Table V shows the
frequencies of enzyme and promoter polymorphisms and of com-
bined polymorphisms in male patients with early-onset psoriasis
compared with male controls. Compared with the association
between disease and the TNFα-238*A allele independent from
other polymorphisms [4.1 (1.5–11); p 5 0.0046] the association
was weaker for the TNFα-238*A/GSTM1*0 [2.8 (0.9–9.4); not
significant], of comparable strength for the TNFα-238*A/IL10–
1082*A [3.5 (1.2–10.1); p 5 0.02] and appeared stronger for the
TNFα-238*A/NAT2*4 combined polymorphisms [8.5 (1.1–69.6);
p 5 0.021]; however, the numbers of individuals with combined
polymorphisms were small and corrected p-values were not signi-
ficant (Table V). The frequencies of combined TNFα-238 and
enzyme or IL10–1082 promoter polymorphisms were similar in
female type I patients and controls, and type II patients and controls
DISCUSSION
In this case-control study a significant association was observed
between familial early-onset but not sporadic late-onset psoriasis
and the G→A polymorphism at position –238 of the TNF-α
promoter. The study confirms in a larger population the finding
of two previous studies reporting the same association. Together
these findings strongly suggest that the TNFα-238*A allele is a
risk factor for susceptibility to psoriasis.
In this study the frequency of the TNFα-238*A allele in type I
patients (27 of 100) was lower than the frequencies observed by
Arias et al (1997; 29 of 64) and Ho¨hler et al (1997; 23 of 60) in
Caucasian patients. In all three studies patients were recruited
locally, and ethnicity among Caucasians could account for the
difference, but the similar TNFα-238*A allele frequency in the
locally recruited controls (this study: 9.8%; Arias: 8.9%; Ho¨hler:
7%) argues against this explanation. With our striking new finding
of an overrepresentation of the TNFα-238*A allele in male type
I patients only, the difference could alternatively be due to
differences in the proportions of males and females enrolled into
the studies. The paper by Arias et al (1997) did not include
information about the gender of recruited patients. In the study by
Ho¨hler et al (1997) the proportions of males and females in the
control group and in the early-onset group were similar to the
proportions in our study, but TNF238*A allele frequencies were
reported to be similar among male and female patients. Gender
influences the inheritance of psoriasis as documented by a paternal
effect on disease susceptibility in affected families (Traupe et al,
1992; Burden et al, 1998); however, this finding is not related to
our observation. Clearly, the different distribution of the TNFα-
238 polymorphism in male and female type I patients needs to be
controlled in future studies. It will be interesting to see whether
there are gender-specific variations in the role of this polymorphism
as a risk factor in psoriasis. All other polymorphisms investigated
in this study were evenly distributed among the sexes.
As the TNFα-238 promoter polymorphism is in linkage disequi-
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librium with HLA-B and HLA-DR loci (Wilson et al, 1993;
D’Alfonso and Richiardi, 1994), it is possible that the observed
association at least partly reflects the known linkage between these
HLA loci and the disease. Noteworthy, Ho¨hler et al (1997) showed
that the TNFα-238*A allele is associated with a higher relative
risk to develop psoriasis than HLA class I antigens. In addition,
there is no proof yet of a direct functional involvement of HLA as
antigen-presenting molecules in psoriasis, whereas an increased
production of TNF-α has been detected in lesional skin, peripheral
blood mononuclear cells and sera of psoriasis patients (Bonifati et al,
1994; Uyemura et al, 1993; Ettehadi et al, 1994; Asadullah et al,
1998), and is likely to play an important part in various phases of
psoriatic skin inflammation (Barker et al, 1991). As the TNF-238
polymorphism lies in a putative regulatory box of the TNF-α
promoter region (D’Alfonso and Richiardi, 1994), a genetically
determined alteration of the cytokine production constitutes a
mechanism for the involvement of the TNFα-238*A allele in the
disease pathogenesis; however, several findings point to a more
complex role of TNF-α promoter polymorphisms in psoriasis. In
vitro studies have shown a significantly increased production of
TNF-α in association with the TNFα-308*A allele (Wilson et al,
1997), but not in association with the TNFα-238*A allele (Pociot
et al, 1995). It appears therefore paradoxical that in our study as
well in the two previous studies (Arias et al, 1997; Ho¨hler et al,
1997) the frequency of the TNFα-308*A allele was lower in type
I patients than in controls, although the negative association was
only of borderline significance. It is possible that the –238 or –308
polymorphisms do not themselves regulate the production of TNF-
α, but are in linkage disequilibrium with certain microsatellite
alleles of the TNFα gene that have been shown to affect TNF-α
levels (Turner et al, 1995).
A cutaneous overproduction of TNF-α may also result from
a defective production of IL-10, an anti-inflammatory cytokine
that inhibits the synthesis of proinflammatory cytokines, chemo-
kines, and inflammatory enzymes in activated macrophages,
T cells, and neutrophils (Moore et al, 1993). In normal skin,
upregulation of endogenous IL-10 production is a key mechanism
in the suppression of T cell driven immune responses (Ferguson
et al, 1994; Li et al, 1994); however, expression of IL-10 is
weak or absent in psoriatic skin compared with other inflammatory
dermatoses (Nickoloff et al, 1994; Asadullah et al, 1998). The
59 flanking region of the IL10 gene, which controls transcription,
is polymorphic. In addition to two microsatellite loci located
1.2 kb and 4.0 kb upstream of the coding region, there are
three single base-pair substitutions at positions –1082, –819,
and –592 that produce three different haplotypes, GCC, ACC,
and ATA (Turner et al, 1997). Peripheral blood mononuclear
cells from individuals carrying an A at position
–1082 (IL10–1082*A) showed significantly lower inducible IL-10
levels compared with individuals negative for an A at this position,
and this correlation was independent of the polymorphisms at
positions –819 and –592 (Turner et al, 1997). In this study we
therefore focused on polymorphisms at position –1082. We were
unable to detect associations between early- or late-onset psoriasis
and the IL10–1082*A allele, and there was no evidence for
significant interactions between the TNFα-238 and IL10–1082
polymorphisms. These data do, of course, not exclude the
possibility that the distribution of the ATA and ACC haplotypes
or of particular combinations of microsatellite alleles varies
between psoriasis patients and healthy controls, the latter
being also associated with differential IL-10 secretion (Eskdale
et al, 1998b).
The second focus of this study was the analysis of polymorphisms
of xenobiotic metabolizing enzymes. N-acetyltransferase 2 catalyzes
the acetylation of primary amino and hydroxylamino groups and
plays a central part in the metabolic pathways that produce or
prevent toxicity following exposure to homocyclic and heterocyclic
arylamine and hydralazine xenobiotics. Combinations of any two
of 15 mutant alleles identified until now define a slow acetylator
genotype, while rapid acetylators have one or two wild-type alleles
(Grant et al, 1997). GST are a complex multigene family of enzymes
that conjugate electrophiles with reduced glutathione. An important
biologic function is the protection against inflammation, muta-
genicity, and genotoxicity as a result of oxidative stress. Homozygous
gene deletions with an abolition of enzymatic function have been
elucidated for GST M1 (Seidegård et al, 1988) and T1 (Pemble
et al, 1994). In addition to the well established role of NAT2 and
GST polymorphisms as risk factors in human cancer, enzyme
polymorphisms have also been implicated in the susceptibility to
inflammatory reactions of the intestine (Duncan et al, 1995) and,
more recently, the skin (Kerb et al, 1997; Schnuch et al, 1998). We
found no significant associations between psoriasis and a rapid
acetylator genotype or homozygous deletion of GST. As there is a
biologic variability in NAT2 phenotype expression of certain NAT2
genotypes (Cascorbi et al, 1995), however, this finding does not
automatically exclude an association between the disease and the
acetylator status. To gain more information about the acetylator
status in psoriasis we analyzed simultaneously the NAT2 genotype
and phenotype in a subgroup of study participants (84 controls, 55
type I, 36 type II). Interestingly, there was a significant association
between early-onset but not late-onset psoriasis and a rapid
acetylator phenotype [OR 2.7 (1.3–5.5); p 5 0.0096] that was not
present at the genotypic level [1.8 (0.9–3.7); p 5 0.11]. Moreover,
we found NAT2 to be constitutively expressed in normal and
psoriatic skin suggesting a direct effect of NAT2 polymorphisms
on the local generation of metabolites from arylamines in food,
cigarette smoking, or environmental amines of various types. As
NAT2 was detected in keratinocytes and Langerhans cells, the
enzyme may participate in cutaneous antigen processing, a critical
step in the induction of inflammatory T cell responses (Anderson
et al, 1995). At a functional level complex interactions between
polymorphic enzymes affecting the ‘‘preimmunologic phase’’ and
cytokine promoter polymorphisms affecting the ‘‘immunologic
phase’’ of cutaneous immune responses may occur. It may be
speculated that these underlie our finding that males carrying the
GSTM1*0 and TNFα-238*A alleles were not at an increased risk
to develop psoriasis [OR 2.8 (0.9–9.4); p 5 0.11] whereas males
carrying the NAT2*4 and TNFα-238*A alleles were over eight
times more likely to develop the disease [8.5 (1.1–69.6); p 5 0.021;
Table V]. Corrected p-values were not significant, however, and
interactions between cytokine promoter and enzyme polymorph-
isms will have to be addressed in larger studies in the future.
According to current knowledge psoriasis has a complex genetic
basis, involving one or more major determinants and a variety
of associated genetic factors that may contribute to the disease
manifestation or control certain aspects of the disease but are no
major predisposing genes themselves. The results of our study in
concert with the findings of two previous reports (Arias et al, 1997;
Ho¨hler et al, 1997) clearly suggest that the TNFα-238*A allele is
a risk factor for susceptibility to early-onset psoriasis; however, as
neither HLA nor TNFα loci have been shown to be linked to
susceptibility loci identified by replicated linkage analyses in affected
families, both loci do not appear to represent major genes. A
genetically determined overproduction of proinflammatory cyto-
kines could lower the threshold for the manifestation of cutaneous
inflammatory reactions in response to physical, chemical, or anti-
genic stimuli. Clinical observations such as the well-established
Koebner’s phenomenon (i.e., the development of psoriatic lesions
after nonspecific irritation of normal appearing skin) and the high
rate of contact sensitizations (Heule et al, 1998) support the presence
of an inflammatory predisposition in psoriasis.
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